利拉鲁肽致胰腺炎的文献病例分析

卢翠翠; 弭玮; 李霞; 张旭升; 沈承武

doi:10.6039/j.issn.1001-0408.2023.12.14

您当前的位置：

首页 >

文章列表页 >

利拉鲁肽致胰腺炎的文献病例分析

药物与临床 | 更新时间：2023-06-26

- 利拉鲁肽致胰腺炎的文献病例分析
- Literature case analysis of liraglutide-induced pancreatitis
- 中国药房 2023年34卷第12期页码：1483-1487
- 作者机构：
  
  1.山东第一医科大学附属省立医院药学部，济南　250021
  2.山东省药品不良反应监测中心，济南　250014
- 作者简介：
  
  副主任药师，博士。研究方向：临床药学。电话：0531-68776449。E-mail：cece2021@163.com
  主任药师，硕士。研究方向：医院药学。电话：0531-68776461。E-mail：scw_810@163.com
- 基金信息：
  
  山东省药品化妆品不良反应监测哨点课题(2022SDADRKY01);山东省医学会临床药学科研专项资金项目(YXH2022ZX001);医院药物警戒研究协作组医院药学科研专项课题(DRM2022018)
- DOI：10.6039/j.issn.1001-0408.2023.12.14
  中图分类号： R969.3
- 纸质出版日期：2023-06-30，
  
  收稿日期：2023-02-13，
  
  修回日期：2023-05-25，
扫描看全文
卢翠翠,弭玮,李霞等.利拉鲁肽致胰腺炎的文献病例分析 ^Δ[J].中国药房,2023,34(12):1483-1487.

LU Cuicui,MI Wei,LI Xia,et al.Literature case analysis of liraglutide-induced pancreatitis[J].ZHONGGUO YAOFANG,2023,34(12):1483-1487.
卢翠翠,弭玮,李霞等.利拉鲁肽致胰腺炎的文献病例分析 ^Δ[J].中国药房,2023,34(12):1483-1487. DOI： 10.6039/j.issn.1001-0408.2023.12.14.

LU Cuicui,MI Wei,LI Xia,et al.Literature case analysis of liraglutide-induced pancreatitis[J].ZHONGGUO YAOFANG,2023,34(12):1483-1487. DOI： 10.6039/j.issn.1001-0408.2023.12.14.

摘要

目的

分析利拉鲁肽致胰腺炎的临床特点，为临床合理用药提供参考。

方法

计算机检索中国知网、维普网、万方数据、PubMed、Web of Science和Medline数据库，收集利拉鲁肽致胰腺炎的个案报道，检索时限为从建库起至2022年12月31日，描述性分析患者人口学特征、用药情况、临床表现、干预与转归等。

结果

共纳入文献17篇，涉及17例患者，其中男性7例、女性10例，年龄为25～75岁；均有用药指征，包括2型糖尿病14例，肥胖或超重3例；其中单一用药5例，合并用药12例。17例患者胰腺炎的发生时间均为利拉鲁肽用药后1 d～11个月，大多出现在6个月以内（14例）；主要临床表现包括腹痛、恶心和呕吐等。诊断为胰腺炎后，16例停用利拉鲁肽，其中1例未予其他干预，15例予以对症治疗，16例患者症状均缓解，但2例在利拉鲁肽停用数周后再次发生胰腺炎，且均为重度胰腺炎，1例患者再次应用利拉鲁肽后胰腺炎再次发生。关联性评价结果显示，1例为“肯定”，4例为“可能”，其余患者为“很可能”。

结论

利拉鲁肽致胰腺炎多发生在用药6个月内，多为轻度、中重度，但也可能出现严重甚至致命的病例。临床在应用利拉鲁肽时，应定期监测患者胰酶水平并密切观察其临床表现，若出现疑似利拉鲁肽诱发的胰腺炎，应尽早停药并给予对症治疗。

Abstract

OBJECTIVE

To analyze the clinical characteristics of liraglutide-induced pancreatitis， and to provide reference for clinical rational drug use.

METHODS

Retrieved from CNKI， VIP， Wanfang database， PubMed， Web of Science and Medline， case reports about liraglutide-induced pancreatitis were collected from the inception to December 31st， 2022. Demographic characteristics， drug use， clinical manifestations， intervention and outcome were analyzed using descriptive statistical method.

RESULTS

A total of 17 pieces of literature were collected and 17 patients were involved， including 7 males and 10 females. The patients aged from 25 to 75 years. All 17 patients had drug indications， including 14 cases of type 2 diabetes mellitus， 3 cases of obesity or overweight. Among 17 patients， liraglutide was used alone in 5 cases， and combined with other drugs in 12 cases. Time from liraglutide administration to pancreatitis occurrence ranged from 1 day to 11 months after medication in 17 patients， with 14 cases less than 6 months. The clinical manifestations mainly included abdominal pain， nausea and vomiting， etc. After the diagnosis of pancreatitis， liraglutide discontinuation occurred in 16 patients； 1 case did not receive any other interventions and the other 15 cases were managed with symptomatic supportive treatment； the symptoms of all 16 patients resolved； however， 2 patients suffered from second episode of severe pancreatitis several weeks after liraglutide discontinuation， pancreatitis recurred after liraglutide rechallenge in 1 case. The results of correlation evaluation showed that 1 case was “positive”， 4 cases were “possible”， and the remaining patients were “very likely”.

CONCLUSIONS

Liraglutide-induced pancreatitis mainly occurred within 6 months after drug administration. The majority of liraglutide-induced pancreatitis cases are mild to moderate， but there are also severe and even fatal cases. It is advisable to periodically monitor the level of pancreatic enzymes and closely observe patients’ clinical mani-festations. In case of suspected liraglutide-induced pancreatitis， drug withdrawal and symptomatic treatment should be taken immediately.

关键词

利拉鲁肽胰腺炎2型糖尿病胰高血糖素样肽-1受体激动剂文献病例分析

Keywords

pancreatitistype 2 diabetes mellitusglucagon-like peptide-1 receptor agonistliterature case analysis

references

GENTILELLA R，PECHTNER V，CORCOS A，et al. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment：are they all the same?[J]. Diabetes Metab Res Rev，2019，35（1）：e3070.

DRUCKER D J. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metab，2018，27（4）：740-756.

HTIKE Z Z，ZACCARDI F，PAPAMARGARITIS D，et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes：a systematic review and mixed-treatment comparison analysis[J]. Diabetes Obes Metab，2017，19（4）：524-536.

LEE P H，STOCKTON M D，FRANKS A S. Acute pancrea-titis associated with liraglutide[J]. Ann Pharmacother，2011，45（4）：e22.

BOUREZANE H，KASTLER B，KANTELIP J P. Late and severe acute necrotizing pancreatitis in a patient with liraglutide[J]. Therapie，2012，67（6）：539-543.

KNEZEVICH E，CRNIC T，KERSHAW S，et al. Liraglutide-associated acute pancreatitis[J]. Am J Health Syst Pharm，2012，69（5）：386-389.

TAUNK R，ABDELMESSIEH P，KURTZ L. Liraglutide-induced acute pancreatitis：744[J]. Am J Gastroenterol，2012，107：S308.

NAKATA H，SUGITANI S，YAMAJI S，et al. Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease[J]. Intern Med，2012，51（21）：3045-3049.

FAMULARO G，GASBARRONE L，MINISOLA G. Pancreatitis during treatment with liraglutide[J]. JOP，2012，13（5）：540-541.

JEYARAJ S，SHETTY A S，KUMAR C R，et al. Liraglutide-induced acute pancreatitis[J]. J Assoc Physicians India，2014，62（1）：64-66.

GHABRA M，ALKHOULI M. Liraglutide associated acute pancreatitis：a case report and review of the literature[J]. Am J Gastroenterol，2018，113（Supplement）：S769.

AL-SALAMEH N，SHAH R N，KHARA H S. Dose increment-associated liraglutide-induced acute pancreatitis[J]. Am J Gastroenterol，2019，114（1）：S768.

THEN E O，MADDIKA S，GAYAM V，et al. Liraglutide-induced liver injury with superimposed acute pancreatitis[J]. Am J Gastroenterol，2019，114（1）：S1294-S1295.

NOE Q V. Scientific report：a case of acute pancreatitis due to liraglutide[J]. Rev Espanola De Enfermedades Dig，2019，111（4）：329-330.

ALI GAMEIL M，ELSEBAIE A H. Mildly symptomatic liraglutide-induced acute pancreatitis in a patient with type 2 diabetes mellitus：a case report[J]. Egypt J Intern Med，2020，32（1）：26.

DOLAN R D，BAZARBASHI A N，LO A，et al. Liraglutide-induced hemorrhagic pancreatitis in a nondiabetic patient[J]. ACG Case Rep J，2020，7（5）：e00380.

CHUA M W J，NG Y K. Early onset of acute pancreatitis in a patient on low-dose liraglutide[J]. Diabetes Metab Syndr，2021，15（3）：753-755.

ALSAADOUN A R，ALSAADOUN T R，AL GHUMLAS A K. Liraglutide overdose-induced acute pancreatitis[J]. Cureus，2022，14（1）：e21616.

谷丽，薛松，王萍. 利拉鲁肽致急性胰腺炎一例报告[J]. 社区医学杂志，2020，18（21）：1487-1488，1491.

章开，田英超，曾冰清，等. 利拉鲁肽与恩格列净联用致急性胰腺炎[J]. 药物不良反应杂志，2020，22（10）：601-602.

VINKLEROVÁ I，PROCHÁZKA M，PROCHÁZKA V，et al. Incidence，severity，and etiology of drug-induced acute pancreatitis[J]. Dig Dis Sci，2010，55（10）：2977-2981.

BALANI A R，GRENDELL J H. Drug-induced pancreatitis：incidence，management and prevention[J]. Drug Saf，2008，31（10）：823-837.

NOEL R A，BRAUN D K，PATTERSON R E，et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes：a retrospective cohort study[J]. Diabetes Care，2009，32（5）：834-838.

CHEBANE L，BAGHERI H，HILLAIRE-BUYS D，et al. Drug-induced pancreatitis. A review of French spontaneous reports[J]. Rev Med Interne，2015，36（9）：573-578.

NIINOMI I，HOSOHATA K，OYAMA S，et al. Pharmacovigilance assessment of drug-induced acute pancreatitis using a spontaneous reporting database[J]. Int J Toxicol，2019，38（6）：487-492.

CHUNG E K，LEE J H，JANG D K，et al. Causative agents of drug-induced pancreatitis：a nationwide assessment[J]. Pancreas，2018，47（10）：1328-1336.

WEISSMAN S，AZIZ M，PERUMPAIL R B，et al. Ever-increasing diversity of drug-induced pancreatitis[J]. World J Gastroenterol，2020，26（22）：2902-2915.

ANDERSON S L，TRUJILLO J M. Association of pancrea-titis with glucagon-like peptide-1 agonist use[J]. Ann Pharmacother，2010，44（5）：904-909.

ROUSE R，XU L，STEWART S，et al. High fat diet and GLP-1 drugs induce pancreatic injury in mice[J]. Toxicol Appl Pharmacol，2014，276（2）：104-114.

MATVEYENKO A V，DRY S，COX H I，et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes：interactions with metformin[J]. Diabetes，2009，58（7）：1604-1615.

LI S，XIE K P. Ductal metaplasia in pancreas[J]. Biochim Biophys Acta Rev Cancer，2022，1877（2）：188698.

FAILLIE J L，YU O H，YIN H，et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus[J]. JAMA Intern Med，2016，176（10）：1474-1481.

BARBOSA S C，CABRERA P，GUERRA B，et al. Valproic acid induced necrohemorragic pancreatitis：case report and diagnostic approach in uncommon pancreatitis[J]. Int J Surg Case Rep，2019，60：126-129.

BANKS P A，BOLLEN T L，DERVENIS C，et al. Classification of acute pancreatitis：2012：revision of the Atlanta classification and definitions by international consensus[J]. Gut，2013，62（1）：102-111.

SIMONS-LINARES C R，ELKHOULY M A，SALAZAR M J. Drug-induced acute pancreatitis in adults：an update[J]. Pancreas，2019，48（10）：1263-1273.

ZHENG J，YANG Q J，DANG F T，et al. Drug-induced pancreatitis：an update[J]. Arab J Gastroenterol，2019，20（4）：183-188.

JONES M R，HALL O M，KAYE A M，et al. Drug-induced acute pancreatitis：a review[J]. Ochsner J，2015，15（1）：45-51.

MAJIDI S，GOLEMBIOSKI A，WILSON S L，et al. Acute pancreatitis：etiology，pathology，diagnosis，and treatment[J]. South Med J，2017，110（11）：727-732.

MEDEROS M A，REBER H A，GIRGIS M D. Acute pancreatitis：a review[J]. JAMA，2021，325（4）：382-390.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据